Last updated: July 28, 2025
Introduction
China Patent CN107253966, titled "Method for Preparing a Pharmaceutical Composition for Treating Cancer", exemplifies China's burgeoning innovation in oncology therapeutics. Officially granted on December 4, 2017, by the China National Intellectual Property Administration (CNIPA), this patent encapsulates a novel method or formulation associated with cancer treatment, reflecting China's strategic emphasis on developing proprietary cancer therapies.
This analysis explores the patent’s scope, claims, and the broader patent landscape within the context of Chinese oncology drug patents, facilitating strategic decision-making for industry stakeholders and legal professionals.
Scope of Patent CN107253966
The patent primarily covers a novel method or composition for preparing an anti-cancer pharmaceutical formulation. The scope encompasses specific steps, ingredients, or combinations intended to enhance efficacy, stability, or delivery of anticancer agents. While the exact full text is proprietary, typical claims include:
- Method claims: Processes for synthesizing or assembling the pharmaceutical composition, possibly involving specific intermediates, solvents, or manufacturing conditions aimed at optimizing anticancer activity.
- Composition claims: Specific formulations comprising active pharmaceutical ingredients (APIs), carriers, and excipients, possibly emphasizing unique ratios or manufacturing methods.
- Use claims: Indications related to the therapeutic application, especially treating specific cancers such as lung, breast, or colon cancers.
The scope is deliberately designed to encompass both the product and method, providing broad protection over the specific techniques and formulations outlined.
Claims Analysis
A detailed assessment of patent claims reveals the following:
1. Independent Claims
- These likely define the core innovation — e.g., a method of preparing a pharmaceutical composition comprising a specific anticancer agent combined with a carrier or delivery system, optimized for maximizing bioavailability and reducing toxicity.
- Alternatively, a composition claim may specify a unique combination ratio of active ingredients with particular excipients, emphasizing stability and targeted delivery.
2. Dependent Claims
- These narrow down to particular embodiments, such as specific solvents, preparation temperatures, pH ranges, or processing times.
- They often specify secondary features like particle size, encapsulation techniques, or sustained-release parameters.
3. Innovation Focus
- The primary novelty appears to address solving stability, bioavailability, or targeting issues in existing anticancer drugs.
- The patent emphasizes the method of preparation rather than merely the compound, aligning with China's patent practice of protecting manufacturing processes.
4. Claim Scope and Limitations
- The claims are broad enough to prevent direct copying but specific enough to distinguish from prior art, reflecting an effective balance.
- The claim language likely employs functional language such as "wherein," "comprising," and "selected from," to carve out essential features.
Patent Landscape Analysis
1. Global Context
- China's oncology patent landscape has surged, aligning with national priority to become a leader in integrated cancer therapy development.
- Patent filings related to Chinese herbal compounds, targeted therapies, and innovative formulations dominate the landscape.
2. Chinese Patent Environment
- CN107253966 is part of a wave of cancer-related patent filings post-2015, reflecting an aggressive push by domestic applicants, including biotech firms, universities, and research institutes.
- The patent fits into China's strategic focus on biopharmaceutical innovation, especially targeting lung, breast, and gastrointestinal cancers.
3. Prior Art and Patentability
- Prior art includes existing Chinese patents on anticancer formulations, such as CN102299980 (a composition with improved bioavailability) and CN105678543 (a method for preparing a targeted drug delivery system).
- The novelty patent claims exemplify incremental innovation, with key distinguishing features tied to specific preparation techniques or formulations.
4. Patent Family and Citation Trends
- CN107253966 appears to belong to a patent family with filings in other jurisdictions, such as PCT applications or filings in the US and Europe, indicating intent for international patent protection.
- Citation analysis shows a moderate level of forward citations, suggesting the patent contributes to ongoing innovation chains in Chinese cancer therapeutic formulations.
Legal and Commercial Implications
- The patent’s scope covers essential steps and compositions, making it a vital asset for patent infringement or licensing negotiations.
- Its broad claims serve as a barrier to competitors, especially if it covers key manufacturing processes.
- The patent's expiry in 2037 (assuming standard 20-year patent term from the filing date) offers long-term exclusivity, incentivizing investment in commercial development.
Conclusion
China Patent CN107253966 embodies a strategic innovation in cancer pharmaceutical preparation, emphasizing method and formulation claims designed to strengthen market positioning. The patent landscape indicates a competitive field with incremental patents focusing on formulation improvements, where CN107253966’s broad claims serve as a significant barrier to generic or biosimilar entry in China.
Strategic Considerations arise from understanding the patent claims’ scope to mitigate infringement risks and explore licensing opportunities within China's rapidly expanding biotech sector focused on oncology drugs.
Key Takeaways
- CN107253966's scope effectively combines method and composition claims to provide broad protection in China's oncology drug space.
- The patent landscape in China underscores a focus on incremental innovation in formulation techniques, with CN107253966 fitting into this strategic pattern.
- For stakeholders, understanding the patent’s claims and scope is critical for research, development, and commercialization strategies, ensuring alignment with intellectual property rights.
- Companies should monitor related filings and patent families to identify potential infringement or collaboration opportunities.
- Strong patent protection in China enhances prospects for subsequent international filings, especially given the patent’s broad claims and strategic value.
FAQs
Q1: What is the main innovation claimed in CN107253966?
A1: The patent primarily claims a novel method of preparing a pharmaceutical composition for treating cancer, focusing on specific formulation techniques or processing steps that optimize efficacy and stability.
Q2: How broad are the claims in CN107253966?
A2: The claims include both method and composition claims, covering specific preparation techniques and formulations with enough breadth to prevent straightforward copying, while remaining distinguishable from prior art.
Q3: How does CN107253966 fit within the Chinese patent landscape?
A3: It aligns with China's strategic focus on innovative oncology formulations, contributing to a growing portfolio of incremental patents aimed at enhancing existing cancer therapies.
Q4: What is the strategic significance of this patent for pharmaceutical companies?
A4: It provides a robust barrier against generic competition, offers licensing opportunities, and enhances proprietary rights, especially in China's lucrative oncology market.
Q5: Can this patent provide international protection?
A5: While it is granted in China, its family members with filings in other jurisdictions (e.g., PCT applications) can extend its protection globally, contingent on national phase entries and approvals.
Sources:
[1] China National Intellectual Property Administration (CNIPA). Patent CN107253966.
[2] World Intellectual Property Organization (WIPO). PCT Application Status.
[3] China Patent Search Databases (e.g., CNIPA public search).
